Q3 2018 Vivus Inc Earnings Call
Conference Call VIVUS Inc
VIVUS Inc Conference call will be held on Nov 1, 2018. During the earnings conference call's session VIVUS Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact VIVUS Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
VIVUS is a biopharmaceutical company with two therapies approved by the FDA: Qsymia® (phentermine and topiramate extendedrelease) for chronic weight management and STENDRA® (Avanafil) for erectile dysfunction, or ED. STENDRA is also approved by the European Commission, or EC, under the trade name, SPEDRA, for the treatment of ED in the EU. Qsymia was approved by the FDA in July 2012 as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index, or BMI, of 30 or greater, or obese patients, or a BMI of 27 or greater, or overweight patients, in the presence of at least one weightrelated comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol, or dyslipidemia. Qsymia incorporates a proprietary formulation combining low doses of active ingredients from two previously approved drugs, phentermine and topiramate.Read more Conference Call